Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov;8(11):2391-401.
doi: 10.1111/j.1600-6143.2008.02412.x.

Association of lower costs of pulsatile machine perfusion in renal transplantation from expanded criteria donors

P M Buchanan  1 , K L Lentine, T E Burroughs, M A Schnitzler, P R Salvalaggio
Affiliations

Association of lower costs of pulsatile machine perfusion in renal transplantation from expanded criteria donors

P M Buchanan et al. Am J Transplant. 2008 Nov.

Abstract

Pulsatile machine perfusion (PMP) has been shown to reduce delayed graft function (DGF) in expanded criteria donor (ECD) kidneys. Here, we investigate whether there is a cost benefit associated with PMP utilization in ECD kidney transplants. We analyzed United States Renal Data System (USRDS) data describing Medicare-insured ECD kidney transplant recipients in 1995-2004 (N = 5840). We examined total Medicare payments for transplant hospitalization and annually for 3 years posttransplant according to PMP utilization. After adjusting for other recipient, donor and transplant factors, PMP utilization was associated with a $2130 reduction (p = 0.007) in hospitalization costs. PMP utilization was also associated with lower DGF risk (p < 0.0001). PMP utilization did not predict differences in rejection, graft survival, patient survival, or costs at 1, 2 and 3 years posttransplant. PMP utilization is correlated with lower costs for the transplant hospitalization, which is likely due to the associated reduction in DGF among recipients of PMP kidneys. However, there is no difference in long-term Medicare costs for ECD recipients by PMP utilization. A prospective trial is necessary as it will help determine if the associations seen here are due to PMP utilization and not differences in the population studied.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Graft Survival of Medicare ECD recipients in the USRDS 1995-2004 by PMP utilization.
Figure 2
Figure 2
Patient survival for Medicare ECD recipients in the USRDS 1995-2004 by PMP utilization.
See this image and copyright information in PMC

References

    1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. The New England Journal of Medicine. 1999;341(23):1725–1730. - PubMed
    1. Ojo AO, Hanson JA, Meier-Kriesche HU, Okechukwu CN, Wolfe RA, Leichtman AB, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. Journal of the American Society of Nephrology. 2001;12(3):589–597. - PubMed
    1. Matas AJ, Schnitzler MA. Payment for living donor (vendor) kidneys: a cost-effectiveness analysis. American Journal of Transplantation. 2004;4(2):216–221. - PubMed
    1. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. American Journal of Transplantation. 2007;7(5 Pt 2):1359–1375. - PubMed
    1. Peter SD, Imber CJ, Friend PJ. Liver and kidney perservation by perfusion. The Lancet. 2002;359:604–613. - PubMed

Publication types